This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Clinical features

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

There is an incubation of from 14 days, up to 21 days (1), after which clinical features include:

  • prodromal symptoms - may be none in young children; older children and adults may may present with a 1-5 day prodrome with symptoms like fever, headache, malaise and upper respiratory symptoms (2)
  • pink macular rash -
    • usually the first sign of the disease, seen in 50-80% of rubella infected individuals (2,3)
    • transitory, erythematous maculopapular rash appears over one or two days. It fades within four days, leaving neither staining nor desquamation (1,2)
    • may be mildly pruritic (2)
      • develops behind the ears and on the face and neck and then spreads to the trunk and limbs (1,2)
      • in some patients no rash develops at all
  • cervical lymphadenopathy -
    • may precede the rash by a week and may persist for several weeks (2)
    • post-auricular, sub-occipital and posterior cervical nodes are commonly involved
  • arthralgia & arthritis
    • seen mostly in adolescent and adult women (60-70%)
    • usually fingers, wrists, and knees are affected symmetrically
    • symptoms tend to appear during or shortly after the rash and pain may last for about one to four weeks (2)
  • grittiness of eyes and suffusion of conjunctivae

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.